User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Statin use is associated with improved survival in ovarian cancer: A retrospective populationbased study

Primary tabs

download
  • Open access
  • PDF
  • 3.90 M
Couttenier, Alexandra [UCL] Lacroix, Olivia [UCL] Evelien Vaes [Research Department, Belgian Cancer Registry, Brussels, Belgium] Chris R.Cardwell [Centre for PublicHealth,Queen's University Belfast, Belfast, Northern Ireland] Harlinde De Schutter [Research Department, Belgian Cancer Registry, Brussels, Belgium] Robert, Annie [UCL]

Background Preclinical in vitro and in vivo studies suggest that statins could exhibit anticancer properties in ovarian cancer. Similar effects have also been reported in observational studies but their results remain inconsistent and could be impaired by methodological limitations. This study aimed to investigate whether statin use is associated with improved survival in ovarian cancer patients at the Belgian population-level. Methods All patients with invasive epithelial ovarian cancer diagnosed between 2004 and 2012 were identified from the Belgian Cancer Registry. Vital statuses were obtained from the Crossroads Bank for Social Security and ovarian cancer-specific deaths were identified from death certificates provided by regional administrations. Information on cancer treatments and statin use were retrieved from health insurance databases. Statin use was modelled as a time-varying covariate in Cox regression models to calculate adjusted hazards ratios (HR) and 95% confidence intervals (95%CI) for the association between postdiagnostic exposure to statins and overall- or ovarian cancer-specific mortality within three years after diagnosis. Adjustments were made for age at diagnosis, year of diagnosis, comorbidities, cancer stage, and cancer treatments. Results A total of 5,416 patients with epithelial ovarian cancer met the inclusion criteria. Of these 1,255 (23%) had at least one statin prescription within three years after diagnosis. Postdiagnostic use of statins was associated with a reduced risk of overall mortality (adjusted HR = 0.81, 95%CI:0.72–0.90, p<0.001). In analyses by statin type, this association was only significant for simvastatin (adjusted HR = 0.86, 95%CI:0.74–0.99, p = 0.05) or rosuvastatin (adjusted HR = 0.71, 95%CI:0.55–0.92, p = 0.01). In subgroup analyses by statin prediagnostic use, the protective association for postdiagnostic statin use was only observed in patients who were also using statins before diagnosis (adjusted HR = 0.73, 95%CI:0.64–0.83, p<0.001). Similar results were observed for ovarian cancer-specific mortality. Conclusion In this large nation-wide cohort of ovarian cancer patients postdiagnostic use of statins was associated with improved survival.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2017
Language Anglais
Journal information "PLoS One" - Vol. 12, no.12, p. e0189233 (2017)
Peer reviewed yes
Publisher Public Library of Science
issn 1932-6203
e-issn 1932-6203
Publication status Publié
Affiliation UCL - SSS/IREC/EPID - Pôle d'épidémiologie et biostatistique
Links
  1. Padhy BM, Gupta YK, Drug repositioning: Re-investigating existing drugs for new therapeutic indications, 10.4103/0022-3859.81870
  2. Pantziarka Pan, Bouche Gauthier, Meheus Lydie, Sukhatme Vidula, Sukhatme Vikas P, Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?, 10.2217/fon.14.244
  3. K Banno, Sci World J (2015)
  4. Pantziarka Pan, Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent, 10.3332/ecancer.2014.485
  5. Kaitin K I, DiMasi J A, Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009, 10.1038/clpt.2010.286
  6. Robinson Elizabeth, Fisher Natalie, Stamelos Vasileios, Redman Charles, Richardson Alan, New strategies for the treatment of ovarian cancer: Figure 1, 10.1042/bst20130203
  7. Trétarre Brigitte, Molinié Florence, Woronoff Anne-Sophie, Bossard Nadine, Bessaoud Faiza, Marrer Emilie, Grosclaude Pascale, Guizard Anne-Valérie, Delafosse Patricia, Bara Simona, Velten Michel, Lapôtre-Ledoux Bénédicte, Ligier Karine, Léone Nathalie, Arveux Patrick, Uhry Zoé, Ovarian cancer in France: Trends in incidence, mortality and survival, 1980–2012, 10.1016/j.ygyno.2015.09.013
  8. Baldwin Lauren A., Huang Bin, Miller Rachel W., Tucker Thomas, Goodrich Scott T., Podzielinski Iwona, DeSimone Christopher P., Ueland Fred R., van Nagell John R., Seamon Leigh G., Ten-Year Relative Survival for Epithelial Ovarian Cancer : , 10.1097/aog.0b013e318264f794
  9. Wright Jason D., Chen Ling, Tergas Ana I., Patankar Sonali, Burke William M., Hou June Y., Neugut Alfred I., Ananth Cande V., Hershman Dawn L., Trends in Relative Survival for Ovarian Cancer From 1975 to 2011 : , 10.1097/aog.0000000000000854
  10. Liu Hongli, Liang Shu-Ling, Kumar Sheetal, Weyman Crystal M., Liu Wendy, Zhou Aimin, Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression, 10.1007/s00280-008-0830-7
  11. Horiuchi Akiko, Kikuchi Norihiko, Osada Ryosuke, Wang Cuiju, Hayashi Akiko, Nikaido Toshio, Konishi Ikuo, Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer, 10.1111/j.1349-7006.2008.00977.x
  12. Robinson Elizabeth, Nandi Mandrita, Wilkinson Laurelle L., Arrowsmith D. Mark, Curtis Anthony D.M., Richardson Alan, Preclinical evaluation of statins as a treatment for ovarian cancer, 10.1016/j.ygyno.2013.02.003
  13. Martirosyan Anna, Clendening James W, Goard Carolyn A, Penn Linda Z, Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance, 10.1186/1471-2407-10-103
  14. M Matsuura, Oncol Rep, 25, 41 (2011)
  15. Elmore R. Geoffrey, Ioffe Yevgeniya, Scoles Daniel R., Karlan Beth Y., Li Andrew J., Impact of statin therapy on survival in epithelial ovarian cancer, 10.1016/j.ygyno.2008.06.007
  16. Lavie Ofer, Pinchev Mila, Rennert Hedy S., Segev Yakir, Rennert Gad, The effect of statins on risk and survival of gynecological malignancies, 10.1016/j.ygyno.2013.05.025
  17. Habis Mohammed, Wroblewski Kristen, Bradaric Michael, Ismail Nadia, Yamada S. Diane, Litchfield Lacey, Lengyel Ernst, Romero Iris L., Statin Therapy Is Associated with Improved Survival in Patients with Non-Serous-Papillary Epithelial Ovarian Cancer: A Retrospective Cohort Analysis, 10.1371/journal.pone.0104521
  18. Wet houdende diverse bepalingen betreffende gezondheid van 13 december 2006, artikel 39./Loi portant dispositions diverses en matiere de santé du 13 décembre 2006, article 39. Belgisch Staatsblad, 22 december 2006/Moniteur Belge, 22 décembre 2006
  19. Henau Kris, Van Eycken Elizabeth, Silversmit Geert, Pukkala Eero, Regional variation in incidence for smoking and alcohol related cancers in Belgium, 10.1016/j.canep.2014.10.009
  20. Cancer survival in Belgium, Belgian Cancer Registry. Brussels 2012
  21. Levesque L. E, Hanley J. A, Kezouh A., Suissa S., Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes, 10.1136/bmj.b5087
  22. Chubak J., Boudreau D. M., Wirtz H. S., McKnight B., Weiss N. S., Threats to Validity of Nonrandomized Studies of Postdiagnosis Exposures on Cancer Recurrence and Survival, 10.1093/jnci/djt211
  23. F Vrijens (2016)
  24. Gbelcová Helena, Leníček Martin, Zelenka Jaroslav, Knejzlík Zdeněk, Dvořáková Gabriela, Zadinová Marie, Poučková Pavla, Kudla Michal, Balaž Peter, Ruml Tomáš, Vítek Libor, Differences in antitumor effects of various statins on human pancreatic cancer : Statins and Pancreatic Cancer, 10.1002/ijc.23242
  25. Mueck Alfred O., Seeger Harald, Wallwiener Diethelm, Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells : , 10.1097/01.gme.0000055485.06076.00
  26. Cardwell Chris R., Hicks Blanaid M., Hughes Carmel, Murray Liam J., Statin Use After Diagnosis of Breast Cancer and Survival : A Population-based Cohort Study, 10.1097/ede.0000000000000189
  27. Murtola Teemu J., Visvanathan Kala, Artama Miia, Vainio Harri, Pukkala Eero, Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland, 10.1371/journal.pone.0110231
  28. Mc Menamin Úna C., Murray Liam J., Hughes Carmel M., Cardwell Chris R., Statin use and breast cancer survival: a nationwide cohort study in Scotland, 10.1186/s12885-016-2651-0
  29. Nickels Stefan, Vrieling Alina, Seibold Petra, Heinz Judith, Obi Nadia, Flesch-Janys Dieter, Chang-Claude Jenny, Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient Cohort, 10.1371/journal.pone.0075088
  30. Desai Pinkal, Lehman Amy, Chlebowski Rowan T., Kwan Marilyn L., Arun Monica, Manson JoAnn E., Lavasani Sayeh, Wasswertheil-Smoller Sylvia, Sarto Gloria E., LeBoff Meryl, Cauley Jane, Cote Michele, Beebe-Dimmer Jennifer, Jay Allison, Simon Michael S., Statins and breast cancer stage and mortality in the Women’s Health Initiative, 10.1007/s10552-015-0530-7
  31. Nielsen Sune F., Nordestgaard Børge G., Bojesen Stig E., Statin Use and Reduced Cancer-Related Mortality, 10.1056/nejmoa1201735
  32. Taylor-Harding Barbie, Orsulic Sandra, Karlan Beth Y., Li Andrew J., Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells, 10.1016/j.ygyno.2010.08.017
Bibliographic reference Couttenier, Alexandra ; Lacroix, Olivia ; Evelien Vaes ; Chris R.Cardwell ; Harlinde De Schutter ; et. al. Statin use is associated with improved survival in ovarian cancer: A retrospective populationbased study. In: PLoS One, Vol. 12, no.12, p. e0189233 (2017)
Permanent URL http://hdl.handle.net/2078.1/202698